About

Roberto Guzmán is a Professor of Chemical and Environmental Engineering at the University of Arizona, where he has been a faculty member since 1989. He holds joint appointments in biomedical engineering and pharmacology and toxicology at the same university, and is also an international faculty member in the Nanotechnology Program at the University of Sonora, Mexico. Guzmán received his PhD in chemical engineering/biotechnology from North Carolina State University, where he also completed a postdoctoral year, and holds an MSc from the University of Illinois, Chicago, and a BS from the University of Guanajuato, Mexico. His research focuses on nanoparticle bio/technology and protein purifications, with an emphasis on metal-hybrid nanoparticles for diagnostics and targeted drug delivery therapy, as well as the discovery of biomarkers from biological fluids. His background is rooted in molecular recognition, affinity technology, synthetic chemistry, applied biochemistry, and mathematical modeling. Guzmán's laboratory conducts research at the intersection of synthetic chemistry, biology, medicine, polymer sciences, and engineering, incorporating both experimental and theoretical analysis. His contributions include developing biomedical nanoparticle platforms for drug delivery, imaging, and therapy, as well as creating novel adsorbents for biomarker isolation applicable to various diseases.

Research topics

• Cancer research
• Biology
• Immunology
• Materials science
• Chemistry
• Nanotechnology
• Biochemistry
• Composite material
• Chemical engineering
• Metallurgy

Selected publications

• Organic solution advanced spray-dried microparticulate dry powder of doxycycline hyclate for lung delivery

  Scientific Reports · 2026-03-09

  articleOpen access

  Obstructive sleep apnea (OSA) is a common sleep disorder characterized by the upper airway collapse, leading to interrupted breathing and reduced oxygen levels during sleep. This condition often results in chronic inflammation and is associated with various long-term health problems. To address OSA-related inflammation, an FDA-approved drug, Doxycycline, was formulated in this study as a dry powder inhaler due to its favorable anti-inflammatory properties that was tested in subsequent cellular and animal studies of OSA. This comprehensive and systematic study aimed to develop inhalable excipient-free spray-dried (SD) one-component drug powders of Doxycycline. Advanced organic solution spray-drying in closed mode, with three different feed pump rates (10%, 50%, and 100%), was used to design and produce Doxycycline microparticles in the solid state successfully. The SD Doxycycline formulations comprised hollow, spherical, dimpled particles (<2 μm). The solid-state characterization of SD formulations confirmed the amorphous nature of Doxycycline after spray drying with a glass transition temperature between 82.73 °C and 89.29 °C. However, compared to the raw drug, residual water content was higher in the SD formulation, ranging from 6.4 ± 0.02% w/w in SD Doxycycline at the low feed pump rate to 6.79 ± 0.06% w/w in SD Doxycycline at the high feed pump rate. SD formulations showed good aerosolization behavior with a Respirable Fraction (RF) of >60% with NeoHaler inhaler device (63.19 ± 7.59 to 68.53 ± 3.73%) while HandiHaler showed lower RF (39.61± 0.57 to 53.90 ± 8.03%). The fine particle fraction (FPF) was higher in the NeoHaler group (24.91 ± 1.17 to 36.72 ± 2.01%) compared to HandiHaler (19.61 ± 5.41 to 33.76 ± 5.21%). This could be explained by the difference in median aerodynamic diameter (8.21 ± 2.68 to 4.69± 1.27 μm) in the NeoHaler group compared to (3.07 ± 0.36 to 3.67 ± 0.59 μm) HandiHaler group. Furthermore, in vitro cell viability as a function of lung cell type and drug dose showed 10 µM of Doxycycline as a safe concentration for the A549, H358, H441, and Calu-3 epithelial-like immortal human cell lines. Inhalable dry powder formulation of Doxycycline could offer new treatment options for patients suffering from sleep apnea.

  PublisherOA PDFDOI

• New Method for Estimating Additive Blooming on the Surface of Vulcanised Rubbers

  International Journal of Manufacturing Research · 2025-01-01

  article

  Inderscience is a global company, a dynamic leading independent journal publisher disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas.

  PublisherDOI

• SUSTAINABLE SOLUTIONS FOR INDUSTRIAL WASTEWATER MANAGEMENT USING PERMEABLE CONCRETE AND WATER REUSE FOR FLEET WASHING WITHIN THE FRAMEWORK OF THE CIRCULAR ECONOMY: CASE OF THE COMPANY CONCRETOS DE SINCELEJO

  2025-07-07

  preprintOpen accessSenior author

  One of the main environmental problems in Sincelejo (Sucre) is the inadequate disposal of industrial wastewater, much of which is discharged untreated into the urban drainage system, affecting surface and groundwater bodies. This research proposes a treatment system based on permeable concrete, designed with local materials, allowing for physical filtration of water and its subsequent reuse in activities such as fleet washing (vehicles, machinery, and equipment). Industries with a high environmental impact were identified to implement a low-cost, efficient, and sustainable solution aligned with the principles of the circular economy. The intervention at a concrete plant and a car wash company yielded positive results, demonstrating measurable environmental and economic benefits

  PublisherOA PDFDOI

• Implementación exitosa de lean manufacturing y economía circular: lo que toda empresa debe considerar

  Multidisciplinas de la Ingeniería · 2025-11-09

  articleOpen accessCorresponding

  En este estudio se desarrolló en una investigación documental, descriptiva y de campo, aplicando encuestas diseñadas a partir de los factores críticos identificados en la literatura para la implementación de Lean Manufacturing y Economía Circular. La muestra incluyó 40 empresas localizadas en cuatro parques industriales del estado de Querétaro, parte de los 49 existentes en municipios como El Marqués, Querétaro, Colón, Corregidora, San Juan del Río y Pedro Escobedo, pertenecientes a sectores clave como automotriz, plástico, alimentario, agrícola, entre otros. Los hallazgos evidencian un marcado interés empresarial en incorporar estas metodologías y transitar hacia modelos operativos sostenibles. Sin embargo, persisten barreras relevantes asociadas con la cultura organizacional, la resistencia al cambio y las limitaciones en programas de formación. La integración de Lean Manufacturing y Economía Circular se perfila como una estrategia esencial para fortalecer la competitividad, optimizar procesos y reducir los impactos ambientales en la región, aportando un marco de referencia sólido para la gestión industrial con más de dos décadas de experiencia aplicada.

  PublisherOA PDFDOI

• Supplementary Figure S3 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

  2024-02-22

  preprintOpen access

  &lt;p&gt;Rituximab dose selection based on macrophage phagocytosis in CD20-positive NHL cell lines. Data showed that a rituximab dose of 0.1 nM induced maximal phagocytosis in OCI-Ly3 cells.&lt;/p&gt;

  PublisherDOI

• Supplementary Table S5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

  2024-02-22

  supplementary-materialsOpen access

  &lt;p&gt;Binding coverage of BMS-986351 across the six major SIRPα haplotypes&lt;/p&gt;

  PublisherDOI

• Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

  Cancer Research Communications · 2024 · 9 citations

  • Cancer research
  • Biology
  • Immunology

  In normal cells, binding of the transmembrane protein CD47 to signal regulatory protein-α (SIRPα) on macrophages induces an antiphagocytic signal. Tumor cells hijack this pathway and overexpress CD47 to evade immune destruction. Macrophage antitumor activity can be restored by simultaneously blocking the CD47-SIRPα signaling axis and inducing a prophagocytic signal via tumor-opsonizing antibodies. We identified a novel, fully human mAb (BMS-986351) that binds SIRPα with high affinity. BMS-986351 demonstrated broad binding coverage across SIRPα polymorphisms and potently blocked CD47-SIRPα binding at the CD47 binding site in a dose-dependent manner. In vitro, BMS-986351 increased phagocytic activity against cell lines from solid tumors and hematologic malignancies, and this effect was markedly enhanced when BMS-986351 was combined with the opsonizing antibodies cetuximab and rituximab. A phase I dose-escalation/-expansion study of BMS-986351 for the treatment of advanced solid and hematologic malignancies is underway (NCT03783403). SIGNIFICANCE: Increasing the phagocytotic capabilities of tumor-associated macrophages by modulating macrophage-tumor cell surface signaling via the CD47-SIRPα axis is a novel strategy. Molecules targeting CD47 have potential but its ubiquitous expression necessitates higher therapeutic doses to overcome potential antigen sink effects. The restricted expression pattern of SIRPα may limit toxicities and lower doses of the SIRPα antibody BMS-986351 may overcome target mediated drug disposition while maintaining the desired pharmacology.

  DOI

• Supplementary Table S6 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

  2024-02-22

  supplementary-materialsOpen access

  &lt;p&gt;Pearson correlation coefficient (cc) of SIRPA expression vs each macrophage-related gene in each of the separate TCGA cohorts, sorted high to low based on the mean of the correlation coefficients&lt;/p&gt;

  PublisherOA PDFDOI

• Supplementary Methods from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

  2024-02-22

  preprintOpen access

  &lt;p&gt;Preparation of BMS-986351&lt;/p&gt;

  PublisherOA PDFDOI

• Supplementary Table S1 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

  2024-02-22

  supplementary-materialsOpen access

  &lt;p&gt;Abundance of the most prevalent CD47–SIRPα binding interface haplotypes&lt;/p&gt;

  PublisherDOI

Frequent coauthors

• Brian A. Fox

  Bristol-Myers Squibb (United States)

  30 shared

• Mahan Abbasian

  28 shared

• Preston Adams

  28 shared

• Konstantinos Mavrommatis

  28 shared

• Lawrence Dearth

  28 shared

• David Mikolon

  28 shared

• Kandasamy Hariharan

  28 shared

• Henry Chan

  28 shared

Labs

• Chemical and Environmental EngineeringPI